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Abstract
Background-: Adiponectin is a hormone produced in and released from adipose cells, which has been shown to
have anti-diabetic and anti-inflammatory actions in peripheral cells. Two cell surface adiponectin receptors (ADRs)
mediate the majority of the known biological actions of adiponectin. Thus far, ADR expression in the brain has
been demonstrated in the arcuate and the paraventricular nucleus of hypothalamus, where its activation affects
food intake. Recent findings suggest that levels of circulating adiponectin increase after an ischemic stroke, but the
role of adiponectin receptor activation in stroke pathogenesis and its functional outcome is unclear.
Methods-: Ischemic stroke was induced in C57BL/6 mice by middle cerebral artery occlusion (MCAO) for 1 h,
followed by reperfusion. Primary cortical neuronal cultures were established from individual embryonic neocortex.
For glucose deprivation (GD), cultured neurons were incubated in glucose-free Locke’s medium for 6, 12 or 24 h.
For combined oxygen and glucose deprivation (OGD), neurons were incubated in glucose-free Locke’s medium in
an oxygen-free chamber with 95% N2/5% CO2 atmosphere for either 3, 6, 9, 12 or 24 h. Primary neurons and brain
tissues were analysed for Adiponectin and ADRs using reverse transcriptase polymerase chain reaction (RT-PCR),
immunoblot and immunochemistry methods.
Results-: Cortical neurons express ADR1 and ADR2, and that the levels of ADR1 are increased in neurons in
response to in vitro or in vivo ischemic conditions. Neurons treated with either globular or trimeric adiponectin
exhibited increased vulnerability to oxygen and glucose deprivation which was associated with increased activation
of a pro-apoptotic signaling cascade involving p38 mitogen-activated protein kinase (p38MAPK) and AMP-activated
protein kinase (AMPK).
Conclusions-: This study reveals a novel pathogenic role for adiponectin and adiponectin receptor activation in
ischemic stroke. We show that cortical neurons express ADRs and reveal a pro-apoptotic role for ADR1 activation in
neurons, which may render them vulnerable to ischemic death.
Introduction
Adiponectin is an abundantly expressed adipokine that
is released into the circulation and self-associates to
form homotrimers. Adiponectin trimers further associ-
ate to form hexamers, high molecular weight (HMW)
oligomers and a globular fraction, generated by proteo-
lytic cleavage of full-length adiponectin monomers [1,2].
Adiponectin receptor 1 (ADR1) and adiponectin recep-
tor 2 (ADR2) are the major receptors for adiponectin.
Both ADRs can be activated by all forms of adiponectin
found in the circulation. However, ADR1 has a higher
affinity for globular adiponectin (gAd) over the full-
length forms, whereas ADR2 has a similar affinity for
both isoforms [3]. In addition, HMW oligomers are
reported to be a specific ligand for T-cadherin [4].
ADRs were shown to exert actions in the peripheral tis-
sues by activating the AMP-activated protein kinase a
(AMPKa) [5], p38 mitogen-activated protein kinase
(p38-MAPK) [6] and nuclear factor-kappa B (NFB)
[reviewed in reference [7]]. In the brain, ADRs 1 and 2
are expressed in the arcuate and the paraventricular
nuclei of the hypothalamus, where they regulate feeding
behaviours [8,9]. However, the functions of adiponectin
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still poorly understood.
The cerebral ischemia that occurs in brain cells
affected by a stroke triggers a complex array of molecu-
lar and cellular alterations including activation of signal-
ing pathways that may either contribute to neuronal
damage or protect neurons. Among the pathways
known to be activated in neurons in response to ische-
mia, are those involving AMPKa and P38-MAPK
[10,11]. It was recently reported that levels of circulating
adiponectin increase after an ischemic stroke [12]. How-
ever, it is not known whether ADRs are activated in
neurons in response to ischemic stroke, nor have the
consequences of ADR signaling on the clinical outcome
of a cerebral ischemic event been established. In the
present study we show that both ADR1 and ADR2 are
expressed in cerebral cortical neurons, and that activa-
tion of ADR1 leads to neuronal cell death under
ischemic conditions.
Materials and methods
Animals and Stroke Model
Three-month-old C57BL/6 male mice were used for all
in vivo experiments. All animal experimental procedures
performed were reviewed and approved by the Univer-
sity of Queensland Animal Care and Use Committee.
Transient focal cerebral ischemia was induced by middle
cerebral artery occlusion (MCAO) using the previously
described intraluminal filament method [13]. Briefly,
mice were anesthetized with isoflurane, a midline inci-
sion was made in the neck, and the left external carotid
and pterygopalatine arteries were isolated and ligated
with 5-0 silk thread. The internal carotid artery (ICA)
was occluded at the peripheral site of the bifurcation of
the ICA and the pterygopalatine artery with a small clip,
and the common carotid artery (CCA) was ligated with
5-0 silk thread. The external carotid artery (ECA) was
cut, and a 6-0 nylon monofilament with a tip that was
blunted (0.2-0.22 mm) with a coagulator was inserted
into the ECA. After the clip at the ICA was removed,
the nylon thread was advanced into the middle cerebral
artery (MCA) until light resistance was felt. The nylon
thread and the CCA ligature were removed after 1 h of
occlusion to initiate reperfusion. In the sham operated
group, these arteries were surgically exposed but not
disturbed. At different time points during the reperfu-
sion period, mice were euthanized and brains were
immediately removed and processed for immunoblot
and immunohistochemical analysis.
Patient tissue collection
The case is a 39-year-old man who had an acute brain-
stem stroke. He died on the ninth day after the incident;
due to massive infarcts and obstructive hydrocephalus.
Acute basilar artery occlusion related to atherosclerosis
and associated thrombi were suggested as the possible
causes of death on autopsy [14].
Neuronal cultures
Cortical tissues dissected from C57BL/6 mouse embryos
at the E15 developmental stage were incubated for 15
min in a solution of 2 mg/ml trypsin in-Ca
2+/Mg
2+-free
Hank’s balanced salt solution (HBSS) (Invitrogen, USA)
buffered with 10 mmol/L HEPES. Tissues were then dis-
sociated and cells were plated in 60 or 100-mm diameter
plastic dishes or 24-well plates and maintained at 37°C in
Neurobasal medium containing B-27 supplements (Invi-
trogen, Carlsbad, CA, USA), 2 mmol/L L-glutamine,
0.001% gentamycin sulfate and 1 mmol/L HEPES (pH
7.2). Experiments were performed in 7 to 9-day-old cul-
tures. Approximately 95% of the cells in such cultures
were neurons and the remaining cells were astrocytes.
RT-PCR analysis
PCR primers were designed using Primer3 software and
synthesized by Integrated DNA Technologies, Inc. (Cor-
alville, IA, USA). Total RNA from cultured neurons was
extracted using Trizol reagent (Sigma, St-Louis, MO,
USA). For single-cell RT-PCR analysis, individual neu-
rons were visualized by using a phase-contrast micro-
scope and collected into a micropipette. PCR products
were electrophoresed on a 2% agarose gel, and were
visualized by ethidium bromide staining. Primer
sequences used in this study: ADR1 (forward primer) 5′
TCC TGA CTG GCT GAA AGA CAA CGA 3′, (reverse
primer) 5′ ACA GTG TGG AAG AGC CAG GAG AAA
3′, ADR2 (forward primer) 5′-TGT GCT ACC GGA
TTG GCT TAA GGA-3′, (reverse primer) 5′-TAC ACC
GTG TGG AAG AGC CAT GAA-3′,A c t i n( f o r w a r d
primer) 5′G G CT G TG T CC C A TG T AT3 ′, (reverse
primer) 5′CCG CTC ATT GCC GAT AGT G 3′.
Immunoblot analysis
Lysates of cultured cells were obtained by washing the
cells in ice-cold PBS and resuspending them in cell lysis
buffer. Proteins were extracted from ipsilateral mouse
brain tissue specimens and 40 μgo fp r o t e i nw a ss e p a -
rated by SDS-PAGE (8-12%) and then transferred to a
nitrocellulose membrane. The membrane was blocked
in 5% non-fat milk for 1 h at room temperature, fol-
lowed by an overnight incubation at 4°C with primary
antibodies against: Actin (Sigma); ADR1 (Santacruz,
USA; Alexis, USA), ADR2 (Alexis, USA), APPL-1,
p-AMPK and Cleaved Caspase-3 (Cell Signaling). Mem-
branes were then washed and incubated with secondary
antibodies for 1 h at room temperature °C. Protein
bands were visualized using a chemiluminescence detec-
tion kit (Amersham Biosciences, Piscataway, NJ, USA).
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Neurons grown on 24-chamber microscope slides were
fixed in 4% paraformaldehyde and incubated at 4°C with
primary ADR1 (Santacruz, USA; Alexis, USA), ADR2
(Alexis, USA) antibodies ove r n i g h t ,f o l l o w e db ya2h
incubation with FITC conjugated secondary antibody at
room temperature. Frozen brain sections were incubated
with primary antibodies against ADR1, ADR2 and NeuN
(Millipore, Billerica, MA). Images of cells were acquired
using a Zeiss Axiophot microscope (Oberkochen,
Germany). Formalin-fixed, paraffin embedded human
brain sections were incubated with primary antibodies
against Adiponectin (Abcam, USA), and biotinylated sec-
ondary antibody and avidin-biotin peroxidase complex
(Vector Elite Kit; Vector,B u r l i n g a m e ,C A ,U S A ) .T h e
peroxidase reaction was developed using a peroxidase
substrate kit (diaminobenzidine DAB, SK-4100; Vector).
Glucose and oxygen deprivation and Cell viability
experiments
For glucose deprivation (GD), cultured neurons were incu-
bated in glucose-free Locke’s medium containing (in
mmol/L) 154 NaCl, 5.6 KCl, 2.3 CaCl2,1M g C l 2,
3.6 NaHCO3, 5 HEPES, pH 7.2, supplemented with genta-
mycin (5 mg/L) for 6, 12 or 24 h. For combined oxygen
and glucose deprivation (OGD), neurons were incubated
in glucose-free Locke’s medium in an oxygen-free cham-
ber with 95% N2/5% CO2 atmosphere for either 3, 6, 9, 12
or 24 h. Effects of globular adiponectin (gAd) and trimer
adiponectin (tAd) (CYT-432, CYT-247 Prospec Bio, Israel)
against GD or OGD-induced neuronal cell death were
determined by trypan blue dye exclusion assay.
Statistical Analyses
Statistical comparisons were made by using ANOVA, and
Newman-Keuls post hoc tests for pairwise comparisons.
Results
ADR1 and ADR2 are expressed in cortical neurons, and
their levels increase in response to oxygen and glucose
deprivation
Using single-cell PCR analysis we found that cultured
murine cortical neurons express mRNA for ADR1 and
ADR2 (Figure 1A). In order to determine whether ADR
signaling is involved in neuronal responses to ischemic
conditions, we first evaluated ADR expression levels in
cultured neurons subjected to OGD. OGD exposure
resulted in an increase in the mRNA levels of ADR1, as
well as a transient increase in the mRNA levels of
ADR2 that peaked at 3 hours (Figure 1B). ADR1 protein
levels were also increased during OGD while ADR2
showed a transient increase in protein expression that
peaked at 12 hours after the onset of OGD (Figure 1C).
Confocal microscopy of ADR1 immunoreactivity showed
that ADR1 is present in the cell body, axon and
d e n d r i t e s ,b u ti sa b s e n tf r o mt h en u c l e u s ,o fc u l t u r e d
cortical neurons (Figure 1D). Addition of globular adi-
ponectin to cultured neurons increased the expression
of ADR1 at 6 and 12 hours post-OGD exposure, but
had no effect on ADR2 expression levels (Figure 1E).
Cerebral ischemia induces a rapid increase in ADR
immunoreactivity in the brain
The extensive increase in expression of ADR1 and ADR2
following OGD in vitro encouraged us to examine
whether similar effects occur in vivo following ischemic
damage. Immunoblots of ischemic cortical tissues at dif-
ferent times following ischemic reperfusion demonstrated
increased levels of ADR1 (Figure 2A). In contrast, the
levels of ADR2 remained unchanged following MCAO
and reperfusion (Figure 2A). APPL1 is an adapter protein
involved in ADR1 and ADR2 signaling and enhances the
binding affinities of the ADRs to adiponectin [15].
APPL1 levels were highly expressed in the cortex, and we
observed an increase in its expression levels in response
to MCAO and reperfusion (Figure 2A). In the ipsilateral
cerebral cortex of sham-operated control mice, little or
no immunoreactivity with ADR1 and ADR2 antibodies
was observed. At 6 h after stroke, neurons in the
ischemic cortex exhibited robust ADR1 immunoreactivity
(Figure 2B). In order to see adiponectin accumulate in
the human brain following ischemic stroke, we analysed
brain tissue obtained from a stroke patient at National
Taiwan University Hospital. We observed accumulation
of adiponectin in vessel-like structres (Large arrows) as
well as in parenchyma (small arrows) in human ischemic
brainstem (2C).
ADR activation enhances cortical neuronal death induced
by oxygen and glucose deprivation
Because the activation of AMPK, p38-MAPK and cas-
pase-3 cleavage and their consequent mitochondrial
alterations are implicated in ischemic neuronal death
[10,11], and because ADR signaling activates AMPK and
p38-MAPK, we next measured levels of cleaved caspase-
3, phosphorylated-AMPK (p-AMPK) and p38-MAPK
following GD and OGD in globular adiponectin-treated
neurons compared with vehicle-treated neurons. Globu-
lar adiponectin treatment significantly increased
p-AMPK, p38-MAPK and activated caspase-3 levels as
compared to vehicle-treated neurons suggesting a pro-
apoptotic role for ADRs in neurons under ischemia-like
conditions (Figure 3A &3B respectively). Furthermore,
we analysed GD- and OGD-induced cell death in adipo-
nectin-treated neurons (10 μg/ml; Prospec, Israel) and
compared it with vehicle-treated neurons. Our data
showed that both globular and trimeric adiponectin
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GD and OGD (Figure 3C-F).
Discussion
In the brain, so far, adiponectin receptor expression has
only been shown in the arcuate and the paraventricular
nuclei of hypothalamus [8,9]. We have now identified
the presence of both adiponectin receptors (ADRs 1 &
2) in mice cortical neurons. Confocal microscopy of
ADR1 immunoreactivity shows that ADR1 is present in
the cell body, axon and dendrites, but is absent from
the nucleus, of cultured cortical neurons. As seen in the
immunoblots of cortical neuron cultures, ADR1 expres-
sion was also more prominent in vivo following reperfu-
sion, as compared to ADR2. Adiponectin is widely
known to promote anti-inflammatory effects such as
Figure 1 Neurons express ADR1 and ADR2 and respond to oxygen and glucose deprivation. (A) ADR1 and ADR2 mRNA are present in
cultured cortical neurons determined by single-cell RT-PCR analysis. The numbers indicate the number of neurons from which RNA was
amplified; 1 and 3 cortical neurons consistently yielded a positive PCR signal for the ADR1 and ADR2 with exactly predicted size. (B) Cortical
neurons subjected to OGD for the indicated times show increased levels of ADR1 and ADR2 mRNA in a time-dependent manner. (C)
Immunoblot analysis of proteins in cell lysates of neurons in control cultures and cultures subjected to OGD for 3-24 h. OGD resulted in
increased levels of ADR1 and ADR2 (D) ADR1 immunoreactivity (red) in cultured neurons; cells were counterstained with DAPI (blue) to label all
nuclei. Arrow points to the axon of a neuron and arrowheads point to dendrites of the same neuron. (E) Cortical neurons subjected to OGD
following globular adiponectin treatment show increased levels of ADR1.
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increasing levels of IL-10 and IL1RA [16]. These effects
are believed to confer protection against chronic disease
conditions like atherosclerosis [17] and the metabolic
syndrome [18]. To some extent, these protective effects
are due to the ability of adiponectin to phosphorylate
AMPK via ADRs [19,20]. Conversely, studies investigat-
ing the role of AMPK in neuronal survival/death have
generated much controversy. The discrepancies, seen in
studies performed in vitro,a r em o s tl i k e l yb e c a u s eo f
Figure 2 Cerebral ischemia increases ADRs immunoreactivity in
the brain. (A) Immunoblot analysis of protein samples from the
cerebral cortex of sham operated control mice and mice subjected
to 1 h cerebral ischemia and 1-24 h reperfusion. Ischemia resulted
in rapid increases in the levels of ADRs immunoreactivities in
neurons in the penumbra area (P). (Scale bars: 50 μM). (B) Images of
brain sections showing ADR1 immunoreactivities (green) and NeuN
(neuronal marker) in mice subjected to cerebral ischemia (1 h) and
reperfusion (24 h). (C) Adiponectin accumulates in vessels like
structures (large yellow arrow) and in parenchyma (small yellow
arrow) in the human ischemic brain. (D) Control brain tissue stained
with secondary antibody shows no staining.
Figure 3 ADR activation mediates neuronal cell death
following in vitro ischemia-like conditions. (A, B) Neuronal
cultures were treated with 10 μg of the globular adiponectin (gAd)
and then subjected to OGD for 12 h (A) or GD for 24 h (B). Proteins
in cell lysates were then subjected to immunoblot analysis by using
the indicated antibodies. The gAd treatment enhanced OGD or GD-
induced increases in levels of p-AMPK, p-38 MAPK and activated
caspase-3. (C-D) Globular adiponectin (gAd) and trimeric
adiponectin (tAd) treatment exacerbates OGD induced death of
cultured primary neurons. Neuronal cell death was quantified 12 h
later. Values are mean ± s.e.m. (n = 6-10 cultures). ***P < 0.0001
compared to OGD or vehicle treated OGD value, *P < 0.05
compared to OGD or vehicle treated OGD value. (E) Globular
adiponectin (gAd) treatment exacerbates GD induced death of
cultured primary neurons. Neuronal cell death was quantified 24 h
later. Values are mean ± s.e.m. (n = 6-10 cultures). ***P < 0.0001
compared to GD or vehicle treated GD value.
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the cell type used (e.g., transformed neural tumor cells
versus primary cells). Recently, one group used a more
direct approach by examining animals with selective
gene deletion of AMPKa [10]. AMPKa knockout mice
were protected from experimental ischemic stroke com-
pared with wild-type controls. The beneficial effect of
the AMPK inhibitor, Compound C, supported this detri-
mental effect of AMPK after stroke [10]. The combined
results from these genetic and pharmacological
approaches strongly suggest that activation of AMPK
pathways in the brain is detrimental to neuronal survival
following ischemia. Since ADR signaling is known to
activate AMPK pathways, we hypothesized that the cere-
bral accumulation of adiponectin and its consequent
ADRs activation following ischemic stroke could contri-
bute to neuronal cell death. We therefore, examined the
effect of adiponectin treatment in vitro on levels of
cleaved caspase-3, a hallmark indicator of apoptosis, and
phospho-AMPK, in cultured cortical neurons subjected
to OGD. Consistent with our hypothesis, we found that
ADR1 activation following adiponectin treatment during
OGD, enhanced OGD-induced AMPK and caspase-3
activation, as well as neuronal death, thereby suggesting
a pro-apoptotic role of ADR 1 activation by adiponectin
contributes to neuronal death under ischemic
conditions.
The stress-activated p38-MAPK plays important roles
in transducing stress-related signals by phosphorylating
intracellular enzymes, transcription factors and cytosolic
proteins involved in apoptosis and inflammatory cyto-
kine production. Sustained activation of p38-MAPK has
been shown to be associated with neuronal cell death/
apoptosis following ischemic stroke [22], and inhibition
of this pathway is neuroprotective [23]. Our findings
s u g g e s tt h a tA D R - m e d i a t e dp 3 8 - M A P Kc o n t r i b u t e st o
neuronal death after cerebral ischemia by promoting
apoptotic cascades in neurons. Caspase-3 mediated
apoptosis facilitates synaptic and neurite degeneration
early in the ischemic neuronal death process [24], sug-
gesting a role for this mechanism in the pathogenic
actions of ADR signaling.
It has been proposed that the globular fragment of
adiponectin is generated by proteolytic cleavage, and
recently it has been shown that the cleavage of adipo-
nectin by leukocyte elastase, secreted from activated
monocytes and/or neutrophils, could be responsible for
the generation of the globular fragment of adiponectin
[25]. It has been shown previously that adiponectin
exerts a cerebroprotective action through an endothelial
nitric oxide synthase-dependent mechanism [26]. Nishi-
mura and colleagues showed that Adiponectin-KO mice
exhibited enlarged brain infarction and increased neuro-
logical deficits after ischemia-reperfusion compared with
WT mice [26]. Conversely, systemic administration of
adenoviral vectors expressing full-length murine adipo-
nectin significantly reduced cerebral infarct size in WT
and Adiponectin-KO mice. However, this murine adipo-
nectin does not exclusively comprise the globular frac-
tion and may have the ability to oligomerise into high,
medium and low molecular weight oligomers, thereby
inducing ADR2 activation. However, this study has not
analysed the role of globular adiponectin which has a
higher binding affinity towards ADR1.
The pathophysiological processes in stroke are com-
plex and also involve disruption of the blood-brain bar-
rier (BBB) [27]. It is noteworthy that in response to
ischemic stroke, the microvasculature assumes an
inflammatory phenotype characterized by leukocyte-
endothelial cell adhesion, leukocyte capillary plugging,
endothelial barrier dysfunction and activation of resident
leukocytes including neutrophils [28]. Although the CNS
is normally isolated from the immune system by the
BBB, activated leukocytes can easily infiltrate the CNS
once the BBB is disrupted during ischemic stroke. This
disruption could also facilitate the penetration of full
length adiponectin into injured brain tissues, that could
be further cleaved by leukocytes elastases at the site of
injury [25]. The pathophysiological importance of adipo-
nectin cleavage by leukocyte elastase in vivo remains
unclear. However, various studies using different cell
types have reported a pro-inflammatory role for globular
adiponectin [29-31]. These studies showed globular adi-
ponectin to be a potent stimulator of NFBa n do t h e r
pro-inflammatory genes, which could be detrimental
during an inflammatory pathology like stroke. Another
recently published study by Bråkenhielm and colleagues
showed that adiponectin induced caspase mediated cell
death in endothelial cells [32]. Notably, the physiological
levels of adiponectin in both human and mouse serum
have been reported to range from 2 to 17 μg/ml and
also elevated following inflammatory disease conditions
like preeclampsia and arthritis [29,33,34]. Thus, the con-
centration of adiponectin used in our study (10 μg/ml)
is well within the observed physiological concentration.
Conclusions
This study reveals a novel pathogenic role for adipo-
nectin and adiponectin receptor activation in ischemic
stroke. We show that cortical neurons express adipo-
nectin receptors and levels of ADR1 increase substan-
tially under ischemic conditions, and that addition of
globular or trimeric adiponectin to neurons exacer-
bates cell death. Our results suggest that ischemia-
induced neuronal ADR1 expression may increase the
sensitivity of neurons to circulating levels of adiponec-
tin following stroke, contributing to disease
pathogenesis.
Thundyil et al. Experimental & Translational Stroke Medicine 2010, 2:15
http://www.etsmjournal.com/content/2/1/15
Page 6 of 8List of abbreviations
ADRS: Adiponectin receptors; AMP: Adenosine monophosphate; AMPK:
AMP-activated protein kinase; APPL-1: Adaptor protein, phosphotyrosine
interaction, PH domain and leucine zipper containing 1; BBB: Blood Brain
Barrier; CNS: Central nervous system; CCA: Common carotid artery; ECA:
External carotid artery; GAD: Globular adiponectin; GD: Glucose deprivation;
ICA: Internal carotid artery; MAPK: Mitogen-activated protein kinase; MCA:
Middle cerebral artery; MCAO: Middle cerebral artery occlusion; NFB:
Nuclear factor-kappa B; OGD: Oxygen and glucose deprivation; P38-MAPK:
p38 mitogen-activated protein kinase; RT-PCR: Reverse transcription
polymerase chain reaction; SDS-PAGE: Sodium dodecyl sulfate
polyacrylamide gel electrophoresis; TAD: Trimeric adiponectin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JT designed the study, performed animal and cell culture experiments and
analyzed data. ET and KS performed cell culture experiments and analyzed
data. SCT and YIL collected human tissue and performed
immunohistochemistry experiments. VTK, TMW, SMT, DGJ and MPM
provided lab facilities, helped to interpret data and wrote the manuscript.
TVM designed the study, provided lab facilities, helped to interpret data and
wrote the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by the American Heart Association and
Australian Heart Foundation (to T.V.A.) and by the Intramural Research
Program of the National Institute on Aging.
Author details
1School of Biomedical Sciences, University of Queensland, Brisbane,
Queensland 4072, Australia.
2Department of Neurology and Stroke Center
and Department of Pathology, National Taiwan University Hospital and
National Taiwan University College of Medicine, Taipei, Taiwan.
3Laboratory
of Neurosciences, National Institute on Aging, Intramural Research Program,
Baltimore, MD 21224, USA.
4Department of Pharmaceutical Sciences, School
of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas
79106, USA.
5College of Pharmacy, Sungkyunkwan University, 300
Cheoncheon-dong, Jangan-gu, Suwon 440-746, Republic of Korea.
Received: 24 July 2010 Accepted: 11 August 2010
Published: 11 August 2010
References
1. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT,
Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte
complement-related protein increases fatty acid oxidation in muscle and
causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005-2010.
2. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin
and adiponectin receptors in insulin resistance, diabetes, and the
metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
3. Ogunwobi OO, Beales IL: Globular adiponectin, acting via adiponectin
receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell
proliferation. Mol Cell Endocrinol 2008, 285:43-50.
4. Asada K, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Yoshii J, Yanase K,
Namisaki T, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H:
Crosstalk between high-molecular-weight adiponectin and T-cadherin
during liver fibrosis development in rats. Int J Mol Med 2007, 20:725-729.
5. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M,
Yamaguchi M, Namiki S, Nakayama R, Tabata M, Ogata H, Kubota N,
Takamoto I, Hayashi YK, Yamauchi N, Waki H, Fukayama M, Nishino I,
Tokuyama K, Ueki K, Oike Y, Ishii S, Hirose K, Shimizu T, Touhara K,
Kadowaki T: Adiponectin and AdipoR1 regulate PGC-1alpha and
mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010, 464:1313-1319.
6. Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schäffler A,
Krempl C, Bleyl C, Aslanidis C, Schölmerich J, Buechler C: Adiponectin-
stimulated CXCL8 release in primary human hepatocytes is regulated by
ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J
Physiol Gastrointest Liver Physiol 2009, 297:G611-618.
7. Tang CH, Lu ME: Adiponectin increases motility of human prostate
cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. The
Prostate 2009, 69:1781-1789.
8. Guillod-Maximin E, Roy AF, Vacher CM, Aubourg A, Bailleux V, Lorsignol A,
Pénicaud L, Parquet M, Taouis M: Adiponectin receptors are expressed in
hypothalamus and colocalized with proopiomelanocortin and
neuropeptide Y in rodent arcuate neurons. J Endocrinol 2009, 200:93-105.
9. Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, Varakis JN:
Expression of adiponectin and adiponectin receptors in human pituitary
gland and brain. Neuroendocrinology 2009, 89:38-47.
10. Li J, Zeng Z, Viollet B, Ronnett GV, McCullough LD: Neuroprotective effects
of adenosine monophosphate-activated protein kinase inhibition and
gene deletion in stroke. Stroke 2007, 38:2992-2999.
11. Piao CS, Kim JB, Han PL, Lee JK: Administration of the p38 MAPK inhibitor
SB203580 affords brain protection with a wide therapeutic window
against focal ischemic insult. J Neurosci Res 2003, 73:537-544.
12. Yatomi K, Miyamoto N, Komine-Kobayashi M, Liu M, Oishi H, Arai H,
Hattori N, Urabe T: Pathophysiological dual action of adiponectin after
transient focal ischemia in mouse brain. Brain Res 2009, 1297:169-176.
13. Okun E, Arumugam TV, Tang SC, Gleichmann M, Albeck M, Sredni B,
Mattson MP: The organotellurium compound ammonium trichloro
(dioxoethylene-0,0’) tellurate enhances neuronal survival and improves
functional outcome in an ischemic stroke model in mice. J Neurochem
2007, 102:1232-1241.
14. Jeng JS, Huang KM, Ya YT, Yip PK: Acta Neurologica Taiwanica 2000,
9:311-316.
15. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-
Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ: APPL1 binds to adiponectin
receptors and mediates adiponectin signalling and function. Nat Cell Biol
2006, 8:516-523.
16. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue,
inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
17. Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, Fu Y: Macrophage
adiponectin expression improves insulin sensitivity and protects against
inflammation and atherosclerosis. Diabetes 2010, 59:791-799.
18. Wang JH, Lee CJ, Lee CC, Chen YC, Lee RP, Hsu BG: Fasting adiponectin is
inversely correlated with metabolic syndrome in patients with coronary
artery disease. Intern Med 2010, 49:739-747.
19. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB: Adiponectin
increases fatty acid oxidation in skeletal muscle cells by sequential
activation of AMP-activated protein kinase, p38 mitogen-activated
protein kinase, and peroxisome proliferator-activated receptor alpha.
Diabetes 2006, 55:2562-2570.
20. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S,
Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P,
Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates
glucose utilization and fatty-acid oxidation by activating AMP-activated
protein kinase. Nat Med 2002, 8:1288-1295.
21. Kleman AM, Yuan JY, Aja S, Ronnett GV, Landree LE: Physiological glucose
is critical for optimized neuronal viability and AMPK responsiveness in
vitro. J Neurosci Methods 2008, 167:292-301.
22. Nozaki K, Nishimura M, Hashimoto N: Mitogen-activated protein kinases
and cerebral ischemia. Mol Neurobiol 2001, 23:1-19.
23. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM,
Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K,
Smith BR, Adams JL, Parsons AA: Inhibition of p38 mitogen-activated
protein kinase provides neuroprotection in cerebral focal ischemia. Med
Res Rev 2001, 21:129-145.
24. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD,
Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, Mattson MP:
Pivotal role for neuronal Toll-like receptors in ischemic brain injury and
functional deficits. Proc Natl Acad Sci USA 2007, 104:13798-13803.
25. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A,
Takekawa S, Kadowaki T: Generation of globular fragment of adiponectin
by leukocyte elastase secreted by monocytic cell line THP-1.
Endocrinology 2005, 146:790-796.
26. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK,
Moskowitz MA, Ouchi N: Adiponectin prevents cerebral ischemic injury
through endothelial nitric oxide synthase dependent mechanisms.
Circulation 2008, 117:216-23.
Thundyil et al. Experimental & Translational Stroke Medicine 2010, 2:15
http://www.etsmjournal.com/content/2/1/15
Page 7 of 827. Arumugam TV, Granger DN, Mattson MP: Stroke and T-cells.
Neuromolecular Med 2005, 7:229-242.
28. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A,
Granger DN: CD40/CD40 ligand signaling in mouse cerebral
microvasculature after focal ischemia/reperfusion. Circulation 2005,
111:1690-1696.
29. Haugen F, Drevon CA: Activation of nuclear factor-kappaB by high
molecular weight and globular adiponectin. Endocrinology 2007,
148:5478-86.
30. Hattori Y, Hattori S, Kasai K: Globular Adiponectin Activates Nuclear
Factor-B in Vascular Endothelial Cells, Which in Turn Induces
Expression of Proinflammatory and Adhesion Molecule Genes. Diabetes
Care 2006, 29:139-141.
31. Tomizawa A, Hattori Y, Kasai K, Nakano Y: Adiponectin induces NF-B
activation that leads to suppression of cytokine-induced NF-B
activation in vascular endothelial cells: globular adiponectin vs. high
molecular weight adiponectin. Diabetes and Vascular Disease Research
2008, 5:123-127.
32. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B,
Funahashi T, Cao Y: Adiponectin-induced antiangiogenesis and antitumor
activity involve caspase-mediated endothelial cell apoptosis. Proc Natl
Acad Sci USA 2004, 1018:2476-2481.
33. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K,
Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S,
Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y:
Paradoxical decrease of an adipose-specific protein, adiponectin, in
obesity. Biochem Biophys Res Commun 1999, 257:79-83.
34. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted
protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-53.
doi:10.1186/2040-7378-2-15
Cite this article as: Thundyil et al.: Evidence that adiponectin receptor 1
activation exacerbates ischemic neuronal death. Experimental &
Translational Stroke Medicine 2010 2:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thundyil et al. Experimental & Translational Stroke Medicine 2010, 2:15
http://www.etsmjournal.com/content/2/1/15
Page 8 of 8